The combination of trametinib and anti-Tim-3 monoclonal antibody (mAb) in the treatment of B16-F10 melanoma mice led to the observation that trametinib significantly promoted apoptosis and inhibited cell proliferation. Here, HAVCR2 is linked to melanoma.